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Background: Isolated increase in serum alkaline phosphatase (IISAlp) is frequently observed in liver
transplant recipients visiting outpatient clinics. However, whether the increase is associated with risk
factors or poor survival is unknown.
Methods: We retrospectively reviewed the medical records of liver transplant recipients who were fol-
lowed up during 1999e2009 and had IISAlp 1 month after liver transplantation, which was sustained for
at least 6 months. Clinical parameters, survival, and risk factors were analyzed and compared between
recipients who survived longer than 6 months after transplantation.
Results: Among 307 liver transplant recipients, 44 had IISAlp. Compared with the control group, the
patients with IISAlp were more frequently of the pediatric population, recipients of female donor or
living-related partial liver grafts, and found to have biliary-related pretransplant disorders, lower body
weight, and shorter warm ischemic time (P < 0.01). One patient with IISAlp died of acute myeloid
leukemia during the follow-up period. The mean time to observation of IISAlp after liver transplantation
was 6.3  0.8 months. The mean follow-up duration was 5.5  0.2 years. Stepwise multivariate analysis
showed that being a pediatric or living-related liver transplant recipient was an independent risk factor
for IISAlp, with adjusted hazard ratios (95% conﬁdence interval) of 5.41 (2.59e11.28) and 3.0 (0.98e9.27),
respectively.
Conclusions: Therefore, being a pediatric or living-related liver transplant recipient was an independent
risk factor for IISAlp. However, IISAlp was not associated with poor survival after liver transplantation.
Hence, patients who have undergone liver transplantation do not require frequent routine examination
of serum alkaline phosphatase levels.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Alkaline phosphatase (Alp) is an ectoenzyme present in
many tissues, including those of the liver, bone, intestine, kidney,
placenta, and leukocytes. More than 95% of serum Alp activity is
derived from hepatocytes and osteoblasts.1 Alp plays an active roleolated increase in serum Alp;
aHRs, adjusted hazard ratios;
ous transhepatic cholangio
L, receptor activator of NF-kB
nalTaiwanUniversityHospital,
22312345665104; fax:þ886
gho@ntu.edu.tw (P.-H. Lee).
ciates Ltd. Published by Elsevier Ltin downregulating the secretory activities of the intrahepatic biliary
epithelium, including decreasing bile ﬂow and biliary bicarbonate
excretion.2 Moreover, it is involved in endotoxin detoxiﬁcation and
can reduce organ injuries (i.e., in the lungs, liver, and kidneys) in
conditions such as ischemic-reperfusion damage or septic shock.3e5
Growing children, pregnant women, people consuming a high-fat
diet, and healthy individuals who have the blood group O or B and
secrete the H-blood group substance in the postprandial period
have been found to have abnormally high Alp levels.6,7 Patients
with hepatic, bone, pulmonary, renal, intestinal, and hematopoietic
diseases or malignancies may present with nonspeciﬁc elevation
of serum Alp levels. Hence, in these patients, diagnoses are often
inferred from symptoms, abnormal examination results, or other
existing abnormalities in laboratory test results and are not based
solely on the elevation of serum Alp levels.d. All rights reserved.
Patients who underwent liver transplantation between 1999 and 2009 
n = 307 
Postoperative survival longer than 
6 months 
n = 261 
Died within 6 months after operation 
n = 46 
Liver recipients without IISAlp 
n = 217 
Adult group n = 169 
Pediatric group                n = 46 
Liver recipients with IISAlp 
n = 44 
Adult group n = 15 
Pediatric group n = 29 
Fig. 1. Patient selection process and inclusion/exclusion criteria. IISAlp: isolated
increase in serum alkaline phosphatase.
Table 1
Clinical features of liver transplant recipients with and without IISAlp.
IISAlp With Without P value
n 44 217
Total follow-up period,
mean  SD, month
66.6  13.5 85.2  42.9
Age, years, n (%) <0.01
0e1 10 (22.7) 14 (6.5)
1e5 16 (36.4) 21 (9.7)
5e18 3 (6.8) 11 (5.1)
>18 15 (34.1) 169 (77.9)
Male, n (%) 23 (52.3) 130 (59.9) 0.085
Body weight, mean  SD, kg 26.9  24.3 51.2  23.5 <0.01
Underlying diagnosis
Biliary related,a n (%) 26 (59.1) 66 (30.4) <0.01
Two bile ducts anastomosed, n (%) 3 (6.8) 6 (2.8) 0.37
Donor clinical parameters
Age, mean  SD, years 34.5  9.0 31.8  10.3 0.11
Male, n (%) 14 (31.8) 122 (56.2) <0.01
Living donor, n (%) 40 (90.9) 138 (63.6) <0.01
Alkaline phosphatase
level, mean  SD, U/L
132.4  86.3 135.1  76.5 0.36
Warm ischemic time,
mean  SD, min
42.2  12.1 51.8  19.8 <0.01
Cold ischemic time,
mean  SD, min
148.2  132.3 143.7  133.5 0.89
IISAlp: isolated increase in serum alkaline phosphatase; SD: standard deviation.
a Biliary-related diagnosis: biliary atresia, progressive familial intrahepatic
cholestasis, Alagille syndrome, primary biliary cirrhosis, and primary sclerosing
cholangitis.
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ORIGINAL RESEARCHLiver transplantation has become the standard treatment
strategy for end-stage liver disease. After surgery, liver transplant
recipients visiting outpatient clinics are frequently observed to
have isolated increase in serum Alp (IISAlp), without other
abnormal laboratory test results. In the studies performed by Ari-
kan et al.,8 O’Riordan et al.,9 and Egawa et al.,10 isolated transient
hyperphosphatasemia (<6 months) occurred in 2.8%e4.3% of
pediatric liver transplant recipients. Although transient IISAlp was
found to be benign in some studies,8,11 it may signal the onset of
hepatic dysfunction due to cytomegalovirus infection, organ
rejection, or biliary tract complications.9,12 Thus, whether IISAlp is
associated with risk factors or poor survival in the long term is not
known. The aim of this study was to identify risk factors and
analyze outcomes of liver transplant recipients with IISAlp during
outpatient follow-up.
2. Materials and methods
The present study was conducted in accordance with the Helsinki Declaration of
1975. We retrospectively reviewed the medical records of liver recipients who were
followed up at the National Taiwan University Hospital between January 1999 and
December 2009, had IISAlp at 1 month after liver transplantation, and for whom
IISAlp was sustained for at least 6 months. Serum Alp activity was routinely moni-
tored using a colorimetric method (Hitachi 747; according to the assay conditions
recommended by the International Federation of Clinical Chemistry: 37 C as
incubation temperature and p-nitrophenyl phosphate as substrate) at the time of
serum liver enzyme measurement (normal range used in our hospital laboratory
service: 60e220 IU/L). IISAlp was deﬁned as serum levels higher than 220 IU/L,
without other abnormal liver function test results. Speciﬁcally, the aspartate and
alanine aminotransferase levels and bilirubin levels of the study subjects were
within twice the normal range and lower than 1.5 U/L, respectively. After liver
transplantation surgery, the patients were followed up at least once every 2 months
after discharge from the hospital. A complete liver panel was performed at every
follow-up visit. The clinical parameters of the recipients (age, sex, body weight,
pretransplant diagnosis, and immunosuppressant use) and donors (age, sex, donor
source [living or deceased], Alp level, and warm and cold ischemic times) were
compared with those of the other recipients who survived longer than 6 months
after the operation during the same period. Patient death was considered as the
primary outcome of interest, followed by episodes of biopsy-proven transplant
rejection, biliary complications, renal failure, malignancies, and bone diseases. The
patients were followed up until December 2011. Data have been presented as
mean  standard deviation values. The Student t test, analysis of variance, chi-
square test, or Fisher exact test was used, as appropriate, for the intergroup
comparison of variables. Logistic regressionmodels were used to adjust for potential
confounding factors in the multivariate analysis. The adjusted hazard ratios and
associated 95% conﬁdence intervals (CIs) were based on the results of the logistic
regression analysis with backward selection, taking P values of <0.05 and >0.1 as
inclusion and exclusion criteria, respectively, for variable selection. A 2-sided
P < 0.05 was considered statistically signiﬁcant.
3. Results
Among the 307 liver transplant recipients, 44 (14.5%) had IISAlp.
For the remaining 263 patients, 46 patients who survived less than
6 months were excluded and the remaining 217 liver transplant
recipients who did not have IISAlp were assigned to the control
group (Fig. 1). Compared with the control group, the patients with
IISAlp were more frequently observed to be of the pediatric pop-
ulation, be recipients of female donor or living-related partial
grafts, and have biliary-related pretransplant disorders (biliary
atresia, progressive familial intrahepatic cholestasis, Alagille
syndrome, primary biliary cirrhosis, and primary sclerosing chol-
angitis), lower body weight, and shorter warm ischemic time
(P < 0.01, Table 1). The mean time to observation of the IISAlp after
liver transplantation was 6.3  0.8 months. The mean IISAlps,
stratiﬁed according to age, are shown in Fig. 2. The IISAlps in the
patients aged 1e5 years were signiﬁcantly different from those of
the adult patients (P ¼ 0.016). Among the patients with IISAlp, 33
(75%) received tacrolimus and 11 (25%) received cyclosporine as the
primary immunosuppressant. Among the patients who did not
have IISAlp,155 (71.4%) received tacrolimus and 62 (28.6%) receivedcyclosporine as the primary immunosuppressant (Table 2).
However, the use of immunosuppressants was not signiﬁcantly
associated with the occurrence of IISAlp (P ¼ 0.63). The mean
follow-up time was 5.5  0.2 years.
The adult group had a higher percentage of patients with
elevated gamma-glutamyl transpeptidase levels than the pediatric
group (P ¼ 0.028; Table 3). None of the adult patients with IISAlp
and normal gamma-glutamyl transpeptidase level had an adverse
outcome. One pediatric patient died of acute myeloid leukemia
diagnosed 16 months after IISAlp occurred during the follow-up
period. Three patients had chronic biliary stenosis and underwent
percutaneous transhepatic cholangio drainage, 2 had transplant
rejections, 1 had chronic renal failure requiring hemodialysis, and 1
had recurrence of cholangiocarcinoma. No bone disease was
documented.
In the univariate analysis, belonging to the pediatric group,
having a low body weight, having a biliary-related disease, and
having had a living donor were signiﬁcant risk factors of IISAlp,
with hazard ratios (95% CI) of 7.19 (3.56e14.52), 0.96 (0.95e0.98),
Table 3
Subgroups of patients with IISAlp according to gGT. Adult group had more
percentage of elevated gGT than pediatric group.
gGT Pediatric Adult P-value
Normal 23 7 0.028
Elevated 6 8
IISAlp: isolated increase in serum alkaline phosphatase; gGT: gamma glutamyl
transpeptidase.
Table 4
Crude and adjusted risk factors for IISAlp after liver transplantation.
Fig. 2. Mean IISAlp levels stratiﬁed according to age groups. IISAlp: isolated increase in
serum alkaline phosphatase; *P ¼ 0.016.
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the stepwise multivariate analysis, being a pediatric or living-
related liver transplant recipient was an independent risk factor
of IISAlp, with adjusted hazard ratios (95% CI) of 5.41 (2.59e11.28)
and 3.0 (0.98e9.27), respectively (Table 4).
4. Discussion
In healthy children, serum Alp levels exhibit a tetraphasic
course, with one peak at infancy and another at puberty.13 In our
present study, we demonstrated a similar trend, as shown in Fig. 2.
Approximately one-third of the outpatient pediatric recipients in
our series had IISAlp, which is quite a high proportion compared
with those in 2 previous series.8e10 The difference in proportion
may be due to the varied patient age distribution between the
studies. As demonstrated in our series, the higher the number of
patients in infancy and puberty, the higher the number of patients
with IISAlp. In the adult group with IIISAlp, the levels of Alp was
lower and less varied than those in the pediatric group. In a prior
study, Jersky14 demonstrated enhanced production and excretion
of Alp into the bile after auxiliary liver transplantation. Further-
more, chronic exposure of Alp further increased the Alp and
gamma-glutamyl transpeptidase activities in the intrahepatic bile
ducts and hepatocyte canalicular pole, promoted enlargement of
bile canaliculi, and decreased bile ﬂow and biliary bicarbonate
excretion.2 Therefore, in cases of subclinical biliary stenosis, serum
Alp levels are prone to elevation.Table 2
Immunosuppressive regimens used for liver transplant recipients with and without
IISAlp.
IISAlp With, n Without, n
n 44 217
FK based 29 124
CyA converted to FK 4 31
IIAlp occurred with
CyA 0 e
FK 4 e
CyA based 3 52
FK converted to CyA 8 10
IIAlp occurred with
FK 0 e
CyA 8 e
IISAlp: isolated increase in serum alkaline phosphatase; FK: tacrolimus; CyA:
cyclosporine.Cyclosporine use is associated with increased serum Alp levels
after renal transplantation.15,16 Calcineurin/nuclear factor-activated
T-cell signaling in osteoblasts controls the expression of chemo-
attractants of monocytic osteoclast precursors, thereby coupling
bone formation and bone resorption.17 Calcineurin inhibitors are
also involved in bone remodeling through alteration of the balance
between the receptor activators of NF-kB ligand and osteoprote-
gerin.18,19 Alp production by osteoblasts in these cases occurs
through Wnt signaling activation.20e22 Clinically, cyclosporine and
tacrolimus have been associated with bone loss after liver trans-
plantation.23 However, although the serum Alp level is a marker of
activated osteoblast activity and patient response to treatment of
osteoporosis (index of bone formation), whether IISAlp is associ-
ated with decreased risk of bone loss in organ transplant recipients
remains unknown and requires further study.
One pediatric liver recipient with IISAlp died of de novo acute
myeloid leukemia in our series. Patients with leukemia have
increased Alp activity,24 probably due to the above mentioned
molecular mechanism involving the Wnt signaling pathway. Other
diseases, including acute bowel diseases such as cytomegalovirus
colitis, particularly when inﬂammatory in origin, can trigger high
serum Alp levels in organ recipients.25 Hence, it is prudent to
clinically rule out liver diseases, bone diseases, and infections in
organ recipients taking immunosuppressive drugs.26
In our study, we found that compared to the control group, the
patientswith IISAlpweremore frequentlyof thepediatric population,
recipients of female donor or living-related partial grafts, and have
biliary-related pretransplant disorders, lower body weight, and
shorter warm ischemic time (P < 0.01). Being a pediatric or living-
related liver transplant recipient was an independent risk factor of
IISAlp after statistical adjustment. Receiving a liver transplant at
a young age could be a risk factor of IISAlp owing to the physiological
nature of the elevation of Alp levels, as discussed earlier. In the
case of living-related donor liver transplantation, small bile ducts
and, sometimes, more than 1 bile duct requiring anastomosis areUnivariate analysis Multivariate analysis
HR 95% CI HR 95% CI
Pediatric group 7.19 3.56e14.52* 5.41 2.59e11.28*
Male sex 0.733 0.38e1.41 e
Body weight 0.96 0.95e0.98* e
Biliary-related
underlying diagnosis
3.31 1.70e6.44* e
Two bile ducts
anastomosed
2.52 0.61e10.51 e
Donor age 1.03 0.99e1.06 e
Donor male sex 0.34 0.17e0.68 e
Living donor 5.73 1.98e16.60* 3.0 0.98e9.27$
Donor Alp level 1.0 0.99e1.00 e
Warm ischemic time 0.97 0.94e0.99 e
Cold ischemic time 0.89 0.99e1.00 e
IIAlp: isolated increase in serum alkaline phosphatase; HR: hazard ratio; 95% CI: 95%
conﬁdence interval.
*P < 0.05.
$P ¼ 0.055.
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occurrence of IISAlp. However, in our study, IISAlpwas not associated
with poor survival after liver transplantation. Therefore, our results
indicate that patients who have undergone liver transplantation do
not require frequent routine monitoring of Alp levels.
Our study was retrospective, and the population was hetero-
geneous, ranging from infants to adults; therefore, we performed
a multivariate logistic regression analysis, adjusting for potential
confounding factors. Belonging to the pediatric group and having
a living liver donor were independent risk factors in our model. The
latter factor was shown to have borderline signiﬁcance (P ¼ 0.055);
hence, further conﬁrmatory studies with larger sample sizes are
required to increase statistical power.
5. Conclusion
IISAlp was not associated with poor survival after liver trans-
plantation. Being a pediatric or living-related liver transplant
recipient was an independent risk factor. The physiological varia-
tion in Alp levels in the pediatric group or the subclinical biliary
stenosis in the living-related liver transplant recipients may have
caused the IISAlp after liver transplantation. However, patients who
have undergone liver transplantation do not require frequent
routine monitoring of serum Alp levels.
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